Market Research Logo

Polycythemia Vera - Pipeline Review, H2 2016

Polycythemia Vera - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Polycythemia Vera - Pipeline Review, H2 2016’, provides an overview of the Polycythemia Vera pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Polycythemia Vera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polycythemia Vera and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Polycythemia Vera
    • The report reviews pipeline therapeutics for Polycythemia Vera by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Polycythemia Vera therapeutics and enlists all their major and minor projects
    • The report assesses Polycythemia Vera therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Polycythemia Vera
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Polycythemia Vera
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Polycythemia Vera pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Polycythemia Vera Overview
    Therapeutics Development
    Pipeline Products for Polycythemia Vera - Overview
    Polycythemia Vera - Therapeutics under Development by Companies
    Polycythemia Vera - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Polycythemia Vera - Products under Development by Companies
    Polycythemia Vera - Companies Involved in Therapeutics Development
    ANP Technologies, Inc.
    Bristol-Myers Squibb Company
    F. Hoffmann-La Roche Ltd.
    Galena Biopharma, Inc.
    Gilead Sciences, Inc.
    Italfarmaco S.p.A.
    Karus Therapeutics Limited
    miRagen Therapeutics, Inc.
    Nerviano Medical Sciences S.r.l.
    Novartis AG
    PharmaEssentia Corporation
    Teva Pharmaceutical Industries Ltd.
    Polycythemia Vera - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    anagrelide hydrochloride CR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    arsenic trioxide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dasatinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drug to Inhibit Ribonucleotide Reductase for Polycythemia Vera and Essential Thrombocythemia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    givinostat - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    idelalisib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KA-1463 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    M-009 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    M-012 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MGN-4893 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    momelotinib dihydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NMSP-113 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    peginterferon alfa-2a - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ropeginterferon alfa-2b - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sonidegib phosphate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Polycythemia Vera - Dormant Projects
    Polycythemia Vera - Discontinued Products
    Polycythemia Vera - Product Development Milestones
    Featured News & Press Releases
    May 09, 2016: Merganser Biotech Announces Issuance of U.S. Patent 9,315,545 Covering Development Compound M012
    May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
    Dec 08, 2015: Galena Biopharma Presents Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition
    Nov 06, 2015: Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology Annual Meeting and Exposition
    Mar 05, 2015: AOP Orphan Pharmaceuticals announces progress of pivotal phase III trial PROUD-PV applying Ropeginterferon alfa 2b, a novel, long-acting, mono-pegylated Interferon for treatment of Polycythemia Vera
    Nov 18, 2014: Galena Biopharma Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial
    Oct 10, 2013: AOP Orphan Pharmaceuticals Announces Progress of Pivotal Phase III Trial PROUD-PV of Novel Mono-Pegylated Interferon Alpha 2b for the Treatment of Polycythemia Vera
    Dec 10, 2012: AOP Orphan Pharma Reports Positive Phase II Data Of New Mono-pegylated Interferon Alpha 2b For Treatment Of Polycythemia Vera
    Feb 17, 2011: miRagen Therapeutics Receives Orphan Drug Designation for MGN-4893 for Treatment of Polycythemia Vera
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Polycythemia Vera, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Polycythemia Vera - Pipeline by ANP Technologies, Inc., H2 2016
    Polycythemia Vera - Pipeline by Bristol-Myers Squibb Company, H2 2016
    Polycythemia Vera - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
    Polycythemia Vera - Pipeline by Galena Biopharma, Inc., H2 2016
    Polycythemia Vera - Pipeline by Gilead Sciences, Inc., H2 2016
    Polycythemia Vera - Pipeline by Italfarmaco S.p.A., H2 2016
    Polycythemia Vera - Pipeline by Karus Therapeutics Limited, H2 2016
    Polycythemia Vera - Pipeline by miRagen Therapeutics, Inc., H2 2016
    Polycythemia Vera - Pipeline by Nerviano Medical Sciences S.r.l., H2 2016
    Polycythemia Vera - Pipeline by Novartis AG, H2 2016
    Polycythemia Vera - Pipeline by PharmaEssentia Corporation, H2 2016
    Polycythemia Vera - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Polycythemia Vera - Dormant Projects, H2 2016
    Polycythemia Vera - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Polycythemia Vera, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report